ANGLE PLC A formal communication has also been received from the United States Patent and Trademark Office indicating that grant of the equivalent US patent application is imminent.
The proprietary CellKeep slide is the result of a three-year development effort by ANGLE to address CTC loss endemic in standard laboratory microscopy techniques for the cytological analysis of CTCs. The result is a new device and method to attach cells to the slide, which extensive inhouse testing has demonstrated, eliminates over 70% of CTC loss experienced when using standard techniques.
The Parsortix system efficiently captures CTCs from blood and these remain intact and viable (live) prior to downstream analysis. When visualising CTCs by microscopy there is a critical step to transfer CTCs to a slide for biomarker labelling. In-house testing has shown that standard laboratory techniques, used worldwide, result in a high rate of cell loss (>50%) and cause damage to CTCs. Reducing cell loss to a minimum is critical for subsequent analysis of CTCs as they are present in very low numbers in the blood.
ANGLE has developed the CellKeep slide to reduce cell loss during the transfer of CTCs to the microscope slide and to protect the morphology of the harvested cells. The technique also reduces costs by concentrating the CTCs into a smaller area on the slide, thereby limiting the quantity of high-cost antibodies and imaging time required to identify and analyse cells.
In analytical studies, CTCs were harvested from duplicate cancer patient blood samples and deposited on either standard microscope slides or ANGLE's new CellKeep slides, then processed and stained for CTC biomarkers. The study demonstrated that the use of CellKeep slides significantly increased the identification of CTCs with higher sample positivity rates, and better preservation of CTC morphology and clusters.
The new CellKeep slide is an integral part of ANGLE's Portrait+ CTC staining kit which is available for customers to identify and enumerate CTCs harvested using the Parsortix system.
ANGLE Chief Executive Officer,
ANGLE Chief Scientific Officer,
Contact:
Tel: +44 (0) 1483 343434
Tel: +44 (0) 203 727 1000
About
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix system and associated consumables. The clinical services business is offered through ANGLE's GCP-compliant laboratory. Services include custom assay development and clinical trial sample testing for pharma.
Over 90 peer-reviewed publications have demonstrated the performance of the Parsortix system.
(C) 2024 Electronic News Publishing, source
